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ABSTRACT
To perform early Technology Assessment (TA) of nanotechnology in oncology. The
possibilities of nanotechnology for detection (imaging), diagnosis and treatment of
cancer are subject of different research programs where major investments are con-
cerned. As a range of bio- nanotechnologies is expected to enter the oncology field it
is relevant to consider the various aspects involved in especially early TA. This article
provides two cases of early assessment of (predecessors of) nanotechnologies: Mi-
croarray Analysis and Photodynamic Therapy implementation, which methodology
can be extrapolated to other nanotechnologies in oncology.
Constructive Technology Assessment (CTA) is used for the introduction of technolo-
gies that are still in a dynamic phase of development or in an early stage of diffusion.
The selection of studied aspects in CTA is based on: clinical aspects (safety, efficacy,
and effectiveness), economic (cost-effectiveness), patient related (QoL, ethical/ju-
ridical and psychosocial), organizational aspects (diffusion and adoption) and sce-
nario drafting. The features of the technology and the phase of implementation are
decisive for choices and timing of the specific aspects to be studied. 
A framework was drafted to decide on the relevant aspects. In the first case, early im-
plementation of Microarray Analysis; clinical effectiveness, logistics, patient cen-
teredness and scenario drafting were given priority. Related to the diffusion-phase of
Photodynamic Therapy however other aspects were evaluated, such as early cost-ef-
fectiveness analysis for possible reimbursement. Often CTA will result in a mixed
method design. Especially scenario drafting is a powerful instrument to predict pos-
sible developments that can be anticipated upon in the assessment. 
CTA is appropriate for the study of early implementation of new technologies in on-
cology. In early TA small series often necessitate a mix of quantitative and qualitative
methods. The features of nanotechnology involved are decisive for the selection of
CTA aspects, most likely: safety -especially possible interactions with other technolo-
gies-, ethics, cost-effectiveness and patient centeredness.
Continuously, new technologies emerge in the early detection, diagnosis and treat-
ment of cancer. Related to the field of genomics and proteomics, nanotechnology is
increasingly receiving attention as a promising biotechnology, also in oncology. For
the involved professionals, but especially decision makers, insurance companies, and
government agencies it is a challenge to keep up with these developments. Technol-
ogy Assessment (TA) can be used to evaluate and improve its implementation and
support (policy) decisions. 
Nanotechnology is dealing with the engineering and creation of elements from
materials that are less than 100 nanometers (one-billionth of a meter) in size, es-
pecially single atoms or molecules. Relevant processes of living organisms occur
basically at nanometer scale, elementary biological units like DNA, proteins or cell
membranes are of this dimension. It is anticipated that nanotechnology can have
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an enormous impact on human health1. The possibil-
ities of nanotechnology for detection (imaging), diag-
nosis and treatment of cancer are currently subject of
different research programs2. Examples of nanotech-
nology are: nanowires, sensors that react on mole-
cules related to altered genes; nanoshells that absorb
infrared light and selectively kill tumor tissue;
nanoparticles that are bound to cancer cells in such a
way that they are made visible (molecular imaging) or
enable local drug delivery (targeted therapy) and
nanoarrays3.
At an early stage in technology development, much is
still unclear. Based on the first publications, the views
on promising developments of scientists and industry, a
scope of application domains becomes evident. In the
phase of product development and early feasibility test-
ing and - assessment, both the technology and the exact
delineation of implementation possibilities gradually
become clear. However, the institution involved, the
policy maker or insurance company inevitably face
choices in order to realize meaningful progress4. Future
users are important stakeholders, especially related to
the understanding of nanotechnology; when insuffi-
cient, the resulting limited acceptance might harm the
diffusion speed of the innovation. 
When do we decide whether a new (genomic- or
nano-) technology is ready for implementation in
clinical practice? In the absence of prospective data
on the actual benefits, retrospective data analysis/va-
lidation, expert opinions and bioinformatics play an
important role in early phase decisions. Applying tra-
ditional methodological requirements sometimes
lead to very complicated and expensive (randomized)
designs for prospective studies5. Thus, it might very
well and possibly increasingly be that implementa-
tion of worthwhile but innovative or complex tech-
nology is postponed, in view of the incomplete avail-
able data and debate on the appropriate assessment
methodology.
In literature, there are just a few articles on Health
Technology Assessment (HTA) concerning nanotech-
nology. The aspects researched in these papers are
mainly focused on safety and ethics. The question aris-
es whether these particular aspects are chosen on
grounded methodology, or is it appropriate to study
others, like financial or logistic feasibility, in this early
stage?
Especially in the early phases of technology develop-
ment, there can be close interaction and mutual influ-
ence of both the technology, the environment and the
actors involved and it can take a while before the tech-
nology and its application domain are stable. HTA
commonly presumes a “ceteris paribus” situation,
whereas it has become evident that environment and
technology are often dynamic and mutually influenc-
ing each other. Besides ‘studying’ these changes, ‘influ-
encing’ changes is sometimes necessary to improve ef-
fectiveness. Moreover it is known that the impact of
HTA, which in practice is often constrained to econom-
ic evaluations, is limited; some reasons are the often
unjustified presumption concerning the stability of the
technology and the time lag that evolves between draft-
ing the first study design and deciding about the results
often 5 to 7 years later. The existence of interaction be-
tween various domains of technology development can
make the implementation process more complex. This
asks for a broader HTA approach that takes technology
dynamics into account and leaves room for influencing
the technology or its application during development
and diffusion. 
An appropriate method might be Constructive
Technology Assessment (CTA), especially in the early
dynamic phase of the introduction. Therefore, not on-
ly the new technology should be analyzed, but also
changes in organization and societal environment.
The purpose of CTA is to increase the efficiency and
effectiveness of the technology, leading to an optimal
quality of care and involves an integral assessment of
clinical, economic, patient-related and organizational
parameters6. 
This article provides two cases of early stage imple-
mentation of (predecessors of) nanotechnologies into
clinical practice in oncology, which can be extrapolat-
ed to similar nanotechnologies in this field. The first
case is the introduction of microarray analysis, which
is a predecessor to nanoarrays; macro devices with
nanocomponents. A DNA microarray (also known as
gene or genome chip, DNA chip, or gene array) is a col-
lection of microscopic DNA spots, commonly repre-
senting single genes, arrayed on a solid surface by co-
valent attachment to a chemical matrix. Microarray
technology is known in clinical practice with examples
as the Oncotype DX7 and the 70-gene prognosis signa-
ture8. In this case, the introduction of the 70-gene
prognosis signature will be presented. This technology
proved to outperform traditional criteria in the selec-
tion of patients which need adjuvant systemic treat-
ment in breast cancer. It proved feasible to implement
this complex technology, in 16 community hospitals in
the Netherlands9. The second case is related to
nanoparticles: the implementation of photodynamic
therapy (PDT) in clinical practice. PDT is an applica-
tion for the detection and treatment of nonmelatoma-
tous skin lesions and head and neck tumors. The
Netherlands Cancer Institute is pioneering with this
technology; it is however difficult to stimulate diffu-
sion both because of the limited indication field and
lacking insurance coverage. The technology is relative
simple to use, but expensive and its use is limited to a
small group of early adapter colleagues.
This article provides an overview of experiences in
the methodology of early assessment of the introduc-
tion of (predecessors of ) nanotechnology in oncolo-
gy, which can lead to an outline of design- and
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methodology related aspects of CTA in early nan-
otechnologies.
Methods
Decisions on the design of the CTA method have to
take the features of the technology, the diffusion stage
and the relevant aspects into account; scenarios can be
used to structure this decision process. 
The complexity of a broad CTA using mixed methods in
a proper design, demands a lot of effort, organization,
costs and knowledge on different areas such as psycholo-
gy, economics and medical science. To achieve a man-
ageable design, it is important to select the most appro-
priate aspects to be researched; in addition, finding a bal-
ance between broadness and depth will inevitably play a
role in publishing CTA results. This asks for a thorough
and broad discussion of those aspects in the design
phase of the CTA. To properly study the dynamics, impact
and consequences of a new technology, CTA has to start
before the early majority phase when the new technolo-
gy will be introduced more widely into clinical practice6. 
The design and methods are related to, and deter-
mined by, the different implementation and diffusion
phases, as described by Rogers10. The phases are shaped
like a bell curve related to the numbers of adopters; the
first (innovator) and last (laggards) phase refer to the
smallest numbers. The early adoption phase follows the
innovator phases and describes the implementation in
the first hospitals. The early majority phase deals with the
implementation in other hospitals that are relying on
opinion leaders and want to use established logistics. The
late majority is conservative and waits until there is no
further debate on the validity, reliability or clinical value
of the technology and the logistics are further improved. 
Decisions on which aspect to choose are depending
on the focus of the study and the diffusion phase: Clin-
ical effectiveness (safety, efficacy, effectiveness): this is
mostly researched in the earliest stage of development,
the innovation phase. Economic aspects (cost-effec-
tiveness): usually determined after finishing a trial
with large inclusion numbers, however it is recom-
mended to perform in an earlier stage, the early
adopters’ phase, to anticipate with possible financial
problems. Patient related aspects (ethics, acceptabili-
ty, patient centeredness, psychosocial impact): prefer-
ably measured alongside the clinical trial latest in the
early adopter phase. Organizational aspects (diffusion,
adoption, implementation, accessibility, skills rou-
tine): preferably measured in essential phases of diffu-
sion as every diffusion population from innovators to
laggards can have different adoption characteristics.
Especially, anticipating the knowledge transfer of the
complex biotechnology is an important issue, since
any diffusion of the technology will not take place if it
is not accepted by its users. 
The selection of CTA aspects are based on Douma et al.,
20076.
Clinical Safety, efficacy, effectiveness
Economic Cost-effectiveness
Patient-related Ethical/juridical, acceptability,
psychosocial reactions, patient
centeredness, juridical
Organizational Diffusion, adoption,
implementation, timeliness,
equity, skills/routines/logistics,
education/training, juridical
Scenario/Roadmap Diffusion scenario (using Rogers
phases)
Scenarios, also called ‘road maps’, can be used to pre-
dict and monitor the implementation process through
the various diffusion phases and can support and iden-
tify the need for evaluation or even interfere through
formal decision making6. The method used in the first
case is based on the Royal Dutch Shell approach, using
a most likely course of development with ‘There Is No
Alternative’ (TINA) elements and alternative course
projections represented by ‘what if’-deviations. Techno-
logical roadmaps align and build bridges between the
scenarios, planning for technological forecasting, with
the strategic vision of the institution. The roadmapping
involves collaborative networking among experts from
diverse disciplines11.
Results
Case study 1: Microarray Analysis
In 2002, researchers at the Netherlands Cancer Insti-
tute (NKI, Amsterdam, the Netherlands) identified a 70-
gene prognosis signature using microarray analysis1 for
lymph node-negative breast cancer patients12. This sig-
nature has been validated in three retrospective patient
series8,13,14. It outperforms currently used clinical fac-
tors in predicting disease outcome and overall survival.
Using the 70-gene prognosis signature instead of the
clinical and pathological prognostic factors, the selec-
tion of patients that will benefit most from adjuvant sys-
temic treatment could be more accurate. The fact that it
would take at least 8-10 years to bring the 70-gene prog-
nosis signature into clinical practice, when introducing
it through the usual path of prospective trials, led to the
conclusion that a controlled introduction would be ap-
propriate to evaluate this technology6. Therefore, a Con-
structive Technology Assessment was conducted as a
side study of the clinical RASTER-study (MicroarRAy
PrognoSTics in Breast CancER), a multicenter prospec-
tive observational study, sponsored by the Dutch Board
of Health Care Insurance (DBHCI). The logistics neces-
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sary for profiling was complex, but was successfully im-
plemented in all 16 participating hospitals. Changes in
the pathology process and multidisciplinary decision
making particularly influenced the duration of the im-
plementation, with a mean value of 2.2 months. A de-
fensive attitude of the physicians may have contributed
to an increase number of prescription of adjuvant sys-
temic therapy (because of the Dutch conservative
guidelines) which was not anticipated. However, physi-
cians valued the addition of the 70-gene prognosis sig-
nature information as beneficial for patient manage-
ment. The impact on patients seems to depend on the
communication to the patients and especially the dis-
cordant risk-groups (patients first received the result of
low risk according to the clinical guidelines, followed by
the result of a high risk according to the 70-gene signa-
ture). Because of this occurrence, it was recommended
that patients should be informed about all diagnostic
results in one contact session to reduce negative affects.
Scenario drafting was helpful to map and anticipate on
possible deviating developments, national as well as in-
ternationally. Although the 70-gene prognosis signature
is officially FDA approved and accepted in the USA, re-
lying on only retrospective validation series for cata-
logue decisions, caused serious debate in the Nether-
lands. A professional discussion on validity has
emerged; although considered unlikely by professionals
at the early stage of introduction, this ‘what if-scenario’
proved surprisingly relevant for the Dutch situation. 
Related to a request of a patient an update proved
necessary in the guidelines on patient-rights concern-
ing banked tissue, and this project is being pursued at
present.
Case study 2: Photodynamic therapy
Photodynamic therapy (PDT) is used in the detection
and treatment of cancer. It involves three key compo-
nents: a photosensitizer, light and tissue oxygen. 5-
Aminolaevulinic acid (ALA) is an endogenous cellular
component and is metabolized within the haem
biosynthetic pathway to produce protoporphyrin IX
(PpIX), a potent endogenous photosensitizer. Following
exogenous administration of 5-ALA, PpIX is generated
intracellular, which can then be activated by visible light
for PDT treatment15.
PDT is most applied by nonmelatomatous skin le-
sions (using ALA) and head and neck tumors (using Fos-
can®). Foscan, the photosensitizer meta-tetrahydrox-
yphenylchlorin (mTHPC; Foscan®, Biolitec Pharma, Ed-
inburgh, Scotland), is a photosensitizing agent (a light-
sensitive drug), which contains temoporfin and is used
lately in head and neck cancers. In October 2001, Fos-
can was approved in the European Union. At the mo-
ment, there are negotiations about registration by the
FDA of Foscan in the US. Literature shows that the sur-
vival remains the same as with usual care, but major ad-
vantages in quality of life can be achieved. Usual care
for head and neck tumors is radiotherapy or surgery, of-
ten associated with serious cosmetic or functional mor-
bidity16, 17. The Netherlands Cancer Institute has been
using the PDT technology since 1996; however, the rela-
tively small incidence makes it difficult to obtain data
on large series and hampers further diffusion. The tech-
nology is relatively simple to use, but expensive and un-
known by colleagues. And, like the first case study, part-
ly due to the lack of RCT based evidence, a discussion is
ongoing about the reliability of the treatment. The ques-
tion is, however, whether it is ethical to conduct a RCT,
and for that reason it was decided to conduct a prospec-
tive case study which in turn might not convince critical
colleagues. Subsequently, there arises a dilemma, which
is hard to tackle. To solve this problem, a cost-effective-
ness analysis (CEA) using modeling techniques was
conducted, which eventually made health insurance
companies reconsider the case for possible reimburse-
ment. In the CEA the aspects of costs, utilities (based on
quality of life scores) and retrospective data on survival
were synthesized in two Markov models.
In Table 1 we summarized the results of the two cases.
Discussion
Early assessment of the introduction of nanotechnologies
The wave of nanotechnology innovations asks for a
view on TA taking both the features of the technology
and the dynamics of development and diffusion into ac-
count. We defined which aspects can be studied in a
CTA analysis in the field of nanotechnology and pre-
sented examples in two case studies. In the first case
study of Microarray Analysis the aspects of clinical ef-
fectiveness, efficiency, patient centeredness and the in-
strument of scenario drafting were appropriate to re-
search. In the second case study of Photodynamic Ther-
apy, the aspects of clinical effectiveness, team function-
ing and cost-effectiveness were so far most important,
whereas CEA using modeling techniques proved an im-
portant methodology. 
The two cases show that implementation of two kinds
of (predecessors of) nanotechnology can have different
patterns of adoption and diffusion, and thus have dif-
ferent priorities of research aspects. In Table 1 we sum-
marized the various aspects that can be studied in a CTA
and related these to the two cases and two recent devel-
oped nanotechnologies. 
The two major areas in which nanomedicine is
presently being developed in cancer involve early detec-
tion of the tumor (1) and cancer treatment using target-
ed therapies (2): 
1) Rapid Detection of Single Nucleotide Polymor-
phism (SNP) Using Nano Magnetic Device is a rising
technology in the field of oncology. SNPs in genomic
DNA are known to be related to a number of hereditary
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conditions and cancers. With the help of DNA microar-
rays, a particular assay, labeled with gold nanoparticles
(Au-np), can make the detection of SNPs more efficient
and less time-consuming; it is however not clear what
costs will be involved and what the exact application
field will be18-20.
2) An example of a nano-based drug for e.g., breast or
non-small-cell lung cancer is ‘Abraxane®’, an FDA ap-
proved, paclitaxel protein-bound particles for in-
jectable suspension cancer treatment with nanoscale
devices, which can serve as targeted drug-delivery vehi-
cles capable of carrying chemotherapeutic agents or
therapeutic genes into malignant cells. The use of
Abraxane® as a vehicle, demonstrated in a phase III tri-
al, eliminates the solvent-related toxicities and obviates
the need for steroid and antihistamine premedication21.
The two new technologies are also processed in Table 1,
in order to provide an overview.
In the early development or (early) innovator phase
usually relatively few numbers of patients are involved
and the technology, its exact features and use, is not yet
stable. In a contingent approach, clinical safety, efficacy,
implementation aspects and aspects related to patient-
acceptation might be the most relevant ones in nanotech-
nology. Whether the patient-related ethical aspects
should receive the attention as is given at present is easier
explained from lack of knowledge and generalization than
methodological reasoning. The clinical efficacy in appro-
priate fields of application within oncology is an obvious
aspect of consideration. Furthermore, the costs involved
in the application of nanotechnology in oncology as well
as the temporal costs of introducing this new technology
in clinical practice impacts the feasibility of its use. Pa-
tient-related concerns including acceptability, psychoso-
cial reactions to, and pa-
tient centeredness of this
new and perhaps feared
technology need to be con-
sidered. Finally, organiza-
tional aspects involved
with the process of imple-
mentation of nanotechnol-
ogy within clinical practice
could seriously impact the
quality of care. For exam-
ple, a new technology
might change the needed
skills and routines, and it
requires different levels of
training or team composi-
tion to ensure its adequate
application. 
Data on these aspects
can be derived from clini-
cal trials, combined with
results from qualitative
methods such as inter-
views and questionnaires about the knowledge, opin-
ions, and experiences of the stakeholders that actually
shape the clinical practice of oncology. The results can
be used for scenario drafting. In case the practical de-
velopment seems to differ strongly from the projected
scenario, expert panels or formal decision processes
can be applied to suggest changes to improve the qual-
ity of implementation22. In the early adopters, early ma-
jority phases, costs, patient related aspects and organi-
zational aspects can be analyzed using greater numbers
of patients. As the use and characteristics of the early
majority-, late majority- and laggard adopters can vary,
it is advisable to continue the evaluation during the dif-
ferent phases, in order to assure and improve the quali-
ty of care during the lifecycle of the technology.
As an example of introduction of new technologies
in the health care system, the DBHCI in the Nether-
lands has experimented with a program of controlled
introduction of promising innovations in an early
stage of development from 2004 onwards. The use of
the 70-gene prognosis signature was one of the three
technologies to be studied. Currently, the DBHCI and
the Ministry of Health are discussing the most appro-
priate way of stimulating innovations in order to stim-
ulate early clinical implementation, for instance
through a “Coverage with Evidence Development”-like
program (CED). 
When applied from the early adopter phase on-
wards, it is likely that CED is an appropriate method to
both study the complex features of bio-nanotechnolo-
gy and provide coverage without having to wait on the
finalization of lengthy trials following a methodologi-
cal approach that was developed in a different techno-
logical era.
Table 1 - Selection of early stage CTA aspects
Technologies
Microarray PDT SNP Abraxane®
Clinical Safety v v
Efficacy v v v v
Effectiveness ? ? ?
Economic Cost-effectiveness v
Patient-related Ethics v
Acceptability v
Psychosocial reactions v
Patient centeredness v v
Patient related juridical aspects v v
Organizational Adoption v v ?
Implementation v
Accessibility/equity v v
Skills/routines/logistics v v v
Juridical v v
Education/training
Scenario/Roadmap Diffusion scenario v v
CTA, Constructive Technolgy Assessment; v, evaluated in literature; ?, relevancy not clear or method de-
bated; PDT, photodynamic therapy; SNP, Single Nucleotide Polymorphism.
 
Conclusion
It seems appropriate to apply CTA on promising tech-
nologies in an early stage of development or dynamic
circumstances. As it can involve various methods and
takes technology dynamics into account, an explicit de-
cision on the aspects to be studied is necessary, in rela-
tion to the diffusion phase, in order to prevent unneces-
sary complex study procedures. When the dynamics
and uncertainties are dealt with early in the assessment,
policy makers are facilitated to decide in an earlier
stage, for instance, on the allocation of resources. 
For the nanotechnology introduction in clinical prac-
tice, Table 1 provides relevant aspects to study related to
earlier experiences and the presently known features of
nanotechnology in oncology. So far, safety and ethical
aspects seem to have priority in the literature, but safe-
ty seems not justified for every nano-application. We
think that a more comprehensive route should be fol-
lowed to support decision making in this complex field. 
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